Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Protein C inhibitor (PCI) occurs at high concentration in seminal plasma, and inhibits human glandular kallikrein-2 and, less readily, prostate-specific antigen. Previous studies have localized PCI in the male genital tract. Here we have performed a detailed investigation of PCI expression in the prostatic tissues, metastases, and cell lines. METHODS: Immunohistochemistry, in situ hybridization, and Western blotting were used to study prostatic tissues, metastases, and PC-3, DU-145, and LNCaP cells. RESULTS: PCI was immunolocalized in tissue microarray spots with BPH epithelium (detection rate 100%), PIN lesions (100%), tumors (96%), metastases (88%), and in all cell lines. ISH and WB supported the findings. CONCLUSIONS: PCI is widely expressed in benign prostatic epithelium, and may act as a local regulator of enzymatic activity in seminal fluid, of importance for normal sperm function. Lack of PCI expression in a subpopulation of high-grade tumor cells in combination with maintained protease expression may facilitate invasive growth patterns.

Original publication

DOI

10.1002/pros.10296

Type

Journal article

Journal

Prostate

Publication Date

01/11/2003

Volume

57

Pages

196 - 204

Keywords

Androgens, Blotting, Western, Carcinoma, Cell Line, Tumor, Humans, Immunohistochemistry, In Situ Hybridization, Male, Neoplasms, Hormone-Dependent, Prostate-Specific Antigen, Prostatic Hyperplasia, Prostatic Neoplasms, Protein C Inhibitor, RNA, Neoplasm